1 April 2022 in Journal of Clinical Oncology
PURPOSE: In 2014, data from a comprehensive multiplatform analysis of 496 adult papillary thyroid cancer samples reported by The Cancer Genome Atlas project suggested that reclassification of thyroid cancer into molecular subtypes, RAS-like and BRAF-like, better reflects clinical behavior than sole reliance on pathologic classification. The aim of this study was to categorize the common oncogenic variants in pediatric differentiated thyroid cancer (DTC) and investigate whether mutation subtype classification correlated with the risk of metastasis and response to initial therapy in pediatric DTC. METHODS: Somatic cancer gene panel analysis was completed on DTC from 131 pediatric patients. DTC were categorized into RAS-mutant ( H-K-NRAS), BRAF-mutant ( BRAF p.V600E), and RET/ NTRK fusion ( RET, NTRK1, and NTRK3 fusions) to determine differences between subtype classification in regard to pathologic data (American Joint Committee on Cancer TNM) as well as response to therapy 1 year after initial treatment had been completed. RESULTS: Mutation-based subtype categories were significant in most variables, including age at diagnosis, metastatic behavior, and the likelihood of remission at 1 year. Patients with RET/ NTRK fusions were significantly more likely to have advanced lymph node and distant metastasis and less likely to achieve remission at 1 year than patients within RAS- or BRAF-mut subgroups. CONCLUSION: Our data support that genetic subtyping of pediatric DTC more accurately reflects clinical behavior than sole reliance on pathologic classification with patients with RET/ NTRK fusions having worse outcomes than those with BRAF-mutant disease. Future trials should consider inclusion of molecular subtype into risk stratification.
15 September 2021 in Journal of Clinical Investigation
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer in the pediatric population and represents the second most common malignancy in adolescent females. Historically, PTC has been classified on the basis of histology, however, accumulating data indicate that molecular subtyping based on somatic oncogenic alterations along with gene expression profiling can better predict clinical behavior and may provide opportunities to incorporate oncogene-specific inhibitory therapy to improve the response to radioactive iodine (RAI). In this issue of the JCI, Y.A. Lee, H. Lee, and colleagues showed that oncogenic fusions were more commonly associated with invasive disease, increased expression of MAPK signaling pathway genes (ERK score), and decreased expression of the sodium-iodine symporter, which was restored by RET- and NTRK-inhibitory therapy. These findings lend credence to the idea of reclassifying pediatric thyroid cancers using a three-tiered system, rather than the two-tiered adult system, and open avenues for the treatment of progressive, RAI-refractory PTC in patients.
1 January 2025 in Endocrine Oncology
Objective: Oncocytic thyroid cancer (OTC) accounts for 3–5% of thyroid cancers. Previously classified as a subtype of follicular thyroid cancer (FTC), OTC has been redefined by the World Health Organization due to its distinct histopathological and molecular features. OTC demonstrates a more aggressive clinical course than other differentiated thyroid cancers, with higher rates of distant metastases and is often refractory to radioactive iodine therapy (RAI). This study investigates the transcriptional profiles and immune populations of OTC and FTC to identify key differences in gene signatures and immune cell populations. Methods: We conducted a comparative analysis of the transcriptional profiles of OTC (n = 12), FTC (n = 8), and non-neoplastic thyroid tissues (n = 9) using targeted RNA sequencing and assessed immune composition through multiplexed immunohistochemistry. PD-L1 and CD68 were evaluated by immunostaining consecutive sections. Results: Functional enrichment analysis of differentially expressed genes between OTC and non-neoplastic thyroids revealed upregulation of metabolic pathway genes and downregulation of genes from the cytokine–cytokine receptor pathway. Compared to FTC, OTC cases have decreased expression of thyroid differentiation genes. CD274/PD-L1 was among the top upregulated genes in OTC vs FTC. PD-L1 protein expression in OTC was tumor cell–derived and correlated with CD68+ macrophage presence, particularly in widely invasive cases. Conclusions: The heightened metabolic activity and reduced differentiation of OTC revealed by our transcriptional studies correlate with clinical features such as FDG-PET avidity and diminished RAI response. Marked PD-L1 upregulation in widely invasive OTC suggests immune checkpoint inhibition as a potential therapeutic strategy. Larger, independent studies will be critical to validate these findings.
12 February 2026 in The Journal of Clinical Endocrinology & Metabolism
Context: The Afirma Genomic Sequencing Classifier (GSC) is validated in patients ≥ 21 years with a 96% negative predictive value for malignancy when GSC-(B)enign. Afirma GSC has not been formally studied in patients <21 years of age with indeterminate thyroid nodules (ITNs). Objective: To evaluate Afirma GSC in young patients with ITNs. Design: Retrospective analysis of Afirma GSC testing. Setting: ITNs referred for molecular testing in a real-world setting Participants: Forty-nine ITNs from 49 patients < 21 years of age who had histopathology or 2 years' clinical follow-up data ascertained. Intervention: None. Main outcome measure: Afirma GSC test performance Results: In 49 ITNs from patients aged 9 to 20 years (median 18.5 [interquartile range, 17.3-19.8]), 30 were GSC-B and 19 GSC-(S)uspicious, among which 14 (73.7%) were malignant (ie, true positive) and 5 (26.3%) were benign (ie, false positive). All 30 Afirma GSC-B cases were either histologically (n = 9) or clinically benign (n = 21) (ie, true negative). All 14 malignancies were GSC-S (sensitivity 100% [95% CI, 77-100]); 30/35 clinically or histologically benign cases were GSC-B (specificity 86% [95% CI, 70-95]). Negative predictive value for an Afirma GSC-B result was 100% [95% CI, 88-100]. Genomic alterations were not detected in the 30 GSC-B samples. Among the 14 malignant samples, there were 9 papillary thyroid carcinomas, 1 oncocytic carcinoma, 1 noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and 3 follicular thyroid carcinomas. Conclusion: In young patients with ITNs, the Afirma GSC demonstrated an excellent negative predictive value when defining a thyroid nodule result by histology or clinical follow-up.
1 January 2025 in Archives of Endocrinology and Metabolism
Objective: This study aimed to investigate the presence of tertiary lymphoid structures (TLSs) and tumor-infiltrating B cells within the germinal centers of TLSs in the tumor microenvironment of thyroid cancer, utilizing a morphological approach. Materials and methods: Histological samples from patients with papillary thyroid carcinoma (PTC) (n = 112) stained with hematoxylin and eosin were examined. The presence of lymphoid neogenesis in PTC was determined based on morphological features and classified according to TLS location and maturation status. Immunofluorescence [...] Abstract Objective: This study aimed to investigate the presence of tertiary lymphoid structures (TLSs) and tumor-infiltrating B cells within the germinal centers of TLSs in the tumor microenvironment of thyroid cancer, utilizing a morphological approach. Materials and methods: Histological samples from patients with papillary thyroid carcinoma (PTC) (n = 112) stained with hematoxylin and eosin were examined. The presence of lymphoid neogenesis in PTC was determined based on morphological features and classified according to TLS location and maturation status. Immunofluorescence